Abstract-Prostaglandin E 2 (PGE 2 ) EP1 receptors (EP1Rs) may contribute to hypertension and related end-organ damage.
H ypertension is an independent risk factor for major neurological diseases, including stroke, vascular cognitive impairment, and Alzheimer dementia. 1 Cerebral blood vessels are the main target of the deleterious effects of hypertension on the brain. 2 In addition to inducing structural changes in cerebral vessels, hypertension alters cerebrovascular regulatory mechanisms that are critical for the structural and functional integrity of the brain. For example, hypertension suppresses the increase in cerebral blood flow (CBF) induced by neural activity, a vital response that matches local energy demands with the delivery of nutrients through blood flow and disrupts the endothelial regulation of cerebral blood vessels. [3] [4] [5] [6] These alterations compromise cerebrovascular reserves and render the brain more vulnerable to ischemia, setting the stage for devastating diseases, such as stroke and dementia. 2 In models of hypertension induced by angiotensin II (Ang II), an octapeptide thought to play a central role in essential hypertension, 7 the cerebrovascular alterations are mediated by reactive oxygen species (ROS) produced by the enzyme NADPH oxidase. 3 However, the factors modulating the ROS production induced by Ang II in cerebral blood vessels and contributing to the vascular dysfunction are poorly understood.
Prostanoids are powerful lipid mediators that are synthesized from arachidonic acid by cyclooxygenase (COX) 1 and 2 and exert a wide variety of biological effects by acting on multiple G-coupled membrane receptors. 8 In the cardiovascular system, prostanoids have long been implicated both in the normal regulation of vascular tone 9 and in the pathobiology of cardiovascular diseases, including hypertension. 8 Recent evidence suggests that prostaglandin E 2 (PGE 2 ), a prostanoid that acts on 4 receptors (EP1 through EP4), participates in the mechanisms of hypertension and related complications. 10 -12 In particular, EP1 receptors have been implicated in the vasoconstriction and blood pressure elevation induced by Ang II. 11, 13 Furthermore, EP1 receptor antagonists lower blood pressure in spontaneously hypertensive rats and in db/db diabetic mice. 11, 13 However, it is not known whether PGE 2 and EP1 receptors also play a role in the deleterious effects of Ang II on cerebral blood vessels, a key determinant of the end-organ damage to the brain. 2 In this study, we investigated the role of EP1 receptors in the cerebrovascular dysfunction induced by Ang II. Using a mouse model of acute Ang II hypertension, we examined whether PGE 2 and EP1 receptors contribute to the cerebrovascular alterations induced by Ang II and whether these effects involve Ang II-dependent ROS production. In addition, we sought to define the enzymatic sources of PGE 2 and the brain cells involved in PGE 2 synthesis.
Methods
Please see the online Data Supplement at http://hyper.ahajournals. org for a more detailed description of the methods.
General Surgical Procedures
All of the procedures were approved by the institutional animal care and use committee of Weill Cornell Medical College. Studies were conducted in 3-month-old male mice (weight: 27 to 30 g). EP1
Ϫ/Ϫ , COX-1 Ϫ/Ϫ , COX-2 Ϫ/Ϫ , and NADPH oxidase Ϫ/Ϫ (NOX 2 Ϫ/Ϫ ) mice were obtained from in-house colonies. 14 -17 Mice were congenic with the C57Bl/6 strain, and C57Bl/6 mice (The Jackson Laboratory, Bar Harbor, ME) were used as wild-type controls. Mice were anesthetized with isoflurane intubated and artificially ventilated (SAR-830, CWE Inc). 4, 5 Mean arterial pressure (MAP), rectal temperature, and blood gases were monitored and controlled. 4, 5 After surgery, anesthesia was maintained with urethane (750 mg/kg IP) and chloralose (50 mg/kg IP). 4, 5 In some studies, mice were anesthetized with isoflurane and implanted with osmotic minipumps delivering saline or Ang II (600 ng/kg per minute). 3, 4 CBF was tested 14 days after pump implantation.
Monitoring of CBF
CBF was monitored with a laser-Doppler probe (Periflux System 5010, Perimed AB) in a cranial window overlying the somatosensory cortex. 5 CBF was expressed as percentage increases relative to the resting level.
Pharmacological Agents
The COX-1 inhibitor SC-560, the COX-2 inhibitor NS398, PGE 2 , prostaglandin F 2 ␣ (PGF 2 ␣; all from Cayman Chemical), or the EP1 antagonist SC-51089 (Biomol) were dissolved in dimethylsulfoxide and superfused on the somatosensory cortex. 16 
Experimental Protocol
MAP and blood gases are presented in Table S1 (see the online Data Supplement at http://hyper.ahajournals.org). The cranial window was first superfused with Ringer solution (vehicle), and CBF responses were recorded. [3] [4] [5] [6] 18, 19 The whisker-barrel cortex was activated for 60 seconds by stroking the contralateral vibrissae, 4 and the evoked changes in CBF were recorded. The endotheliumdependent vasodilator acetylcholine (ACh; 10 mol/L; Sigma) or the smooth muscle relaxant adenosine (400 mol/L; Sigma) was superfused on the exposed neocortex for 5 minutes. After testing baseline CBF responses, saline or Ang II was infused intravenously at a rate of 0.25Ϯ0.02 g/kg per minute. 4 CBF responses were tested again after 30 to 40 minutes of Ang II or saline infusion in wild-type, EP1, COX-1, COX-2, or NOX2-null mice. In experiments using pharmacological inhibitors, CBF responses were first tested with vehicle superfusion and then after 30 minutes of superfusion with SC51089 (10 mol/L), SC560 (25 mol/L), or NS398 (100 mol/L). Then, the infusion of Ang II was started and CBF responses were tested again 30 to 40 minutes later. In some experiments, the effect of 30 minutes of neocortical application of PGE 2 (1 mol/L) or PGF 2 ␣ (1 mol/L) on the CBF responses was evaluated after Ang II or saline infusion in mice treated with SC560 or in EP1 and NOX2-null mice. 14, 16, 17 In experiments with Ang II administration for 14 days, CBF responses were tested before and after neocortical application of SC51089.
Immunohistochemistry
Coronal brain sections were cut through the somatosensory cortex using a cryostat and incubated with primary antibodies against COX-1, neuronal nuclei, CD31, ionized calcium-binding adaptor molecule 1, glial fibrillary acidic protein, or EP1 receptors. After incubation with a secondary antibody, sections were mounted on slides and examined using a Leica confocal microscope.
ROS Detection
ROS production was assessed by hydroethidine (HE) microfluorography. 5, 6, 15 HE was topically superfused on the somatosensory cortex for 60 minutes. Ringer solution containing HE or HE plus SC51089, SC560, or NS398, was superfused and, 30 minutes later, the intravenous infusion of Ang II or vehicle was started. Mice were killed 30 to 40 minutes later, coronal brain sections were cut through cortex underlying the cranial window, and ROS was determined as described previously. 5, 6, 15 In some experiments, the effect of neocortical application of PGE 2 or PGF 2 ␣ on ROS production after COX-1 or EP1 receptor inhibition was also studied after Ang II or saline infusion.
PGE 2 Assay
Mice were surgically prepared as described above and killed after 30 to 40 minutes of intravenous Ang II infusion. Samples were immediately collected from the somatosensory cortex, and the renal medulla samples were weighed and homogenized, and prostanoid concentration was determined using an enzyme immunoassay kit. 14 
Data Analysis
Data are expressed as meanϮSEM. Two group comparisons were evaluated using the Student t test. Multiple comparisons were evaluated by the ANOVA and the Tukey test. Differences were considered statistically significant for PϽ0.05.
Results

EP1 Receptors Are Required for the Cerebrovascular Effects of Ang II
In agreement with previous studies, [3] [4] [5] [6] 18, 19 administration of Ang II to wild-type mice (nϭ5 per group) elevated MAP (see Table S1 ) and attenuated the increase in CBF evoked by whisker stimulation (Ϫ46Ϯ4%) or by ACh superfusion (Ϫ40Ϯ4%; PϽ0.05, ANOVA and Tukey test) but not adenosine (Figure 1 ; PϽ0.05; see Figure S1 ). In wild-type mice, neocortical superfusion with the EP1 receptor antagonist SC51089 did not alter Ang II hypertension or resting CBF (see Tables S1 and S2 ), but it prevented the attenuation of the CBF responses to whisker stimulation and ACh (Figure 1 ; nϭ5 per group). Similarly, in EP1-null mice, Ang II elevated MAP (see Table S1 ) but failed to attenuate the increased in CBF induced by whisker stimulation or ACh (Figure 1 ; nϭ5 per group). In contrast, topical application of Aß1-40 (5 mol/L for 40 minutes), a peptide that induces cerebrovascular dysfunction through NOX2-derived ROS, 15, 20 attenuated the CBF responses in EP1 nulls (whisker stimulation: Ϫ43Ϯ5%; ACh: Ϫ44Ϯ7; PϽ0.05; nϭ5 per group), indicating that NOX2 is functional in EP1 null mice. Administration of slow-pressor doses of Ang II for 14 days elevated MAP and attenuated the increase in CBF induced by whisker stimulation or ACh (Figure 2A ,B; see Table S1 at http:// hyper.ahajournals.org). The cerebrovascular dysfunction was attenuated by neocortical application of SC51089 ( Figure 2 ; nϭ5 per group; PϽ0.05 from vehicle).
COX-1 But Not COX-2 Inhibition Attenuates the Cerebrovascular Effects of Ang II
The observation that EP1 receptors are required for the cerebrovascular effects of Ang II points to the involvement of PGE 2 , a reaction product of the COX pathway. 8 Therefore, we sought to determine whether the source of PGE 2 was COX-1 or COX-2. Topical superfusion with the COX-2 inhibitor NS398 did not alter resting CBF (see Table S2 ) and attenuated the increase in CBF induced by whisker stimulation but not ACh (Figure 3 ), as described previously. 17 However, NS398 did not affect the attenuation of CBF responses to whisker stimulation or ACh induced by acute Ang II administration (PϽ0.05 from control; nϭ5 per group; Figure 3 ). Similarly, Ang II attenuated the CBF response to whisker stimulation (vehicle: 15Ϯ1%; Ang II: 10Ϯ1%) and ACh (vehicle: 22Ϯ1%; Ang II: 13Ϯ1%) in COX-2 null mice (PϽ0.05 from wild type; nϭ5 per group). Superfusion with the COX-1 inhibitor SC560 lowered resting CBF but not the increase in CBF evoked by whisker stimulation or ACh ( Figure 3 ; nϭ5 per group). 16 However, SC560 prevented the attenuation of these responses induced by Ang II without altering the CBF response to adenosine ( Figure 3 ; see Figure S1 and Table S1 ; nϭ5 per group). Similarly, Ang II failed to attenuate the increase in CBF induced by whisker stimulation (vehicle: 25Ϯ1%; Ang 
PGE 2 But Not PGF 2 ␣ Counteracts the Effect of COX-1 Inhibition by acting on EP1 Receptors
The findings presented above implicate COX-1-derived PGE 2 in the cerebrovascular alterations induced by Ang II. To test this hypothesis, we examined whether exogenous PGE 2 could re-establish the cerebrovascular effects of Ang II after COX-1 inhibition. On the basis of a dose-response study, we chose a concentration of PGE 2 (1 mol/L) that does not alter resting CBF or the increase in CBF induced by whisker stimulation, ACh, or adenosine ( Figure 1 ; nϭ5 per group; see Table S2 and Figure S2 ). Superfusion with this concentration of PGE 2 re-established the attenuation of the CBF response to whisker stimulation or ACh in mice treated with SC560, whereas PGF 2 ␣ was not effective (Figure 3 ; nϭ5 per group). In contrast, PGE 2 failed to re-establish the cerebrovascular effects of Ang II in wild-type mice treated with the EP1 antagonist SC51089 or in EP1-null mice ( Figure  1 ; nϭ5 per group), attesting to the fact that the effect of PGE 2 requires EP1 receptors. NOX2-null mice are protected from the cerebrovascular dysfunction induced by Ang II. 3 However, PGE 2 did not re-establish the vascular dysfunction induced by Ang II in NOX2-null mice (Figure 4 ; nϭ5 per group), indicating that PGE 2 is upstream of NOX2 in the signaling pathway mediating the cerebrovascular effects of Ang II.
EP1 Receptors and COX-1-Derived PGE 2 Contribute to Ang II-Induced ROS Production
In wild-type mice, Ang II increased ROS production in neocortical cerebral blood vessels, as reported previously 5 ( Figure 5A ; nϭ5 per group). The increase in ROS evoked by Ang II was markedly attenuated by SC51089 superfusion ( Figure 5A ). Furthermore, the ROS increase was attenuated by the COX-1 inhibitor SC560 but not by the COX-2 inhibitor NS398 ( Figure 5B ; nϭ5 per group). In vehicletreated mice, PGE 2 superfusion did not affect baseline ROS production, but, in mice treated with SC560, PGE 2 reestablished the increase in ROS induced by Ang II, whereas PGF 2 ␣ had no effect ( Figure 5 ; nϭ5 per group).
Cellular Localization of COX-1 and EP1 Receptors
In the somatosensory cortex, COX-1 immunoreactivity was localized to small cells with fine ramified processes that were also immunopositive for the microglial marker ionized calcium-binding adaptor molecule 1 (Figure 6 ). COX-1 immunoreactivity was not observed in cerebral blood vessels, identified by the endothelial cell marker CD31 (Figure 6 ), neurons (neuronal nuclei), or astrocytes (glial fibrillary acidic protein, see Figure S3 ). In contrast, EP1 receptor immunoreactivity was observed in CD31
ϩ vascular profiles and neurons ( Figure 6 and see Figure S3 ) but did not colocalize with microglial and astrocytic markers (see Figure S3) . Therefore, COX-1 is present in microglia, whereas EP1 receptors are present in neurons and endothelial cells. 
Effect of
Discussion
We have demonstrated that the cerebrovascular dysfunction induced by acute or chronic Ang II is prevented by the EP1 receptor antagonist SC51089. The COX-1 inhibitor SC560 prevented the cerebrovascular effects of acute Ang II, whereas the COX-2 inhibitor NS398 did not, implicating COX-1 as the enzymatic source of PGE 2 . Measurements of PGE 2 documented that COX-1 is the major source of this prostaglandin in the somatosensory cortex. Neocortical superfusion with PGE 2 reinstated the cerebrovascular effects of Ang II in mice treated with SC560. However, PGE 2 was not effective in mice treated with SC51089 or in EP1-null mice, ruling out the participation of other prostanoid receptors in the effect of PGE 2 . Ang II-induced ROS production was attenuated after inhibition of COX-1 or EP1 receptors, and PGE 2 counteracted the attenuation observed with COX1 inhibition. Using immunocytochemistry to determine the cellular source(s) and targets of PGE 2 , we observed COX-1 in microglia and EP1 receptors in endothelial cells and neurons. These novel findings provide the first evidence that the deleterious cerebrovascular effects of Ang II require COX-1-derived PGE 2 and EP1 receptors. The observation that PGE 2 reinstates the cerebrovascular dysfunction induced by Ang II after COX-1 inhibition cannot be attributed to a deleterious cerebrovascular effect of PGE 2 , because PGE 2 did not alter resting CBF or its response to whisker stimulation, ACh, or adenosine. SC51089 and NS398 did not alter resting CBF, but SC560, as anticipated, 16 produced a small CBF reduction that does not affect the interpretation of the data. Although the concentration of PGE 2 applied to the cerebral cortex (1 mol/L) is larger than the endogenous concentration, we anticipate that the effective concentration reaching the volume of tissue in which CBF was recorded (Ϸ1 mm 3 ) is lower, because the bioavailability of PGE 2 is reduced in biological fluids. 8 In addition, the observation that PGE 2 does not counteract the cerebrovascular dysfunction in mice treated with SC51089 or in EP1-null mice, and that PGF 2 ␣ does not mimic the effects of PGE 2 , rules out nonspecific effects.
We have shown here that in the cerebral cortex, unlike the renal cortex, circulating Ang II does not increase PGE 2 production. This observation is consistent with the wellestablished finding that COX-1, the source of the PGE 2 precursor prostaglandin H 2 in our model, is present in microglial cells, 21 which reside inside the blood-brain barrier and are not accessible to circulating Ang II. It is, therefore, likely that constitutive PGE 2 production by COX-1, rather than Ang II-stimulated PGE 2 production, is required for the expression of the cerebrovascular dysregulation induced by Ang II. Our finding that SC560, but not NS398, reduces baseline PGE 2 production in the neocortex supports this hypothesis. Collectively, our data raise the possibility that microglial COX-1-dependent PGE 2 production plays a role in cerebrovascular dysregulation induced by Ang II. However, we cannot rule out that endothelial COX-1 is expressed below immunocytochemistry detection levels or that COX-1-derived prostaglandin H 2 from microglia is converted to PGE 2 by PGE 2 synthase present in the vessel wall. 22 We found that the increase in ROS induced by Ang II requires COX-1-derived PGE 2 and EP1 receptors. We have demonstrated previously that the increase in ROS induced by circulating Ang II is restricted to cerebrovascular cells, mainly endothelial cells, and is mediated by a NOX2-containing NADPH oxidase. 3, 5 NOX2-derived superoxide reacts with NO derived from endothelial NO synthase to form peroxynitrite, which, in turn, is responsible for the attenuation of endothelium-dependent responses and functional hyperemia. 6 The findings of the present study suggest that constitutive PGE 2 -induced activation of EP1 receptors is needed for Ang II to trigger ROS production from NOX-2. The observation that PGE 2 by itself does not increase ROS indicates that PGE 2 does not affect NADPH oxidase activity directly but that baseline levels of this prostanoid are needed to enable the NADPH oxidase activation induced by Ang II. This scenario is reminiscent of the effect of PGE 2 23 EP1-null mice have been reported previously to have small reductions in resting blood pressure, 10 a finding confirmed here, although the MAP change did not reach statistical significance. An EP1-null mouse developed more recently exhibited reduced resting MAP and an attenuation of the increase in blood pressure induced by Ang II. 11 In our study, we did not observe a reduction in the acute hypertensive effects of Ang II, despite the attenuation of the cerebrovascular effects. The reasons for this discrepancy are not clear, although confounding effects of anesthesia could play a role. Furthermore, the mice used by Guan et al 11 were generated using a different gene-targeting strategy and cannot be directly compared with the EP1-null mice used in the present study. Irrespective of the role of EP1 receptors in the elevation in blood pressure, our findings clearly establish their involvement in the cerebrovascular effects of Ang II.
Essential hypertension attenuates the increase in CBF induced by neural activity, 24 but, to our knowledge, the role of COX inhibitors in such attenuation has not been examined. However, there is evidence that the COX pathway participates in the systemic endothelial dysfunction observed in hypertensive patients. 25 We found that EP1 receptors are essential in the cerebrovascular dysfunction induced by acute or chronic Ang II administration. With chronic Ang II administration, the rescue of the cerebrovascular dysfunction is not complete, suggesting that a component of the dysfunction is mediated by mechanisms independent of EP1 receptors.
Perspectives
We have demonstrated that the vascular dysregulation induced by Ang II requires COX-1-derived PGE 2 acting on EP1 receptors. PGE 2 and EP1 receptors do not increase ROS directly, but they are necessary for the NADPH oxidasedependent ROS production induced by Ang II. Ang II does not increase PGE 2 in the cerebral cortex, indicating that COX-1-dependent constitutive PGE 2 production is involved in the effect. On the basis of the localization of COX-1 in microglia and of EP1 receptors in cerebral arterioles, we speculate that PGE 2 could originate from microglia and acts on vascular EP1 receptors to enable Ang II-induced vascular oxidative stress. These observations provide evidence for a previously unrecognized permissive role of EP1 receptors in the cerebrovascular dysfunction induced by Ang II and raise the possibility that microglial cells are capable of modulating cerebrovascular responses through COX-1-derived PGE 2 .
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SUPPLEMENTAL METHODS General surgical procedures
All procedures were approved by the Institutional Animal Care and Use Committee of Weill Cornell Medical College. Studies were conducted in 3-month-old male mice (weight: 27-30g). EP1-/-, COX-1, COX-2 and NOX2-/-mice were obtained from in house colonies [1] [2] [3] [4] . Mice were congenic with the C57Bl/6 strain and C57Bl/6 mice (The Jackson Laboratory) were used as wild type controls. Mice were anesthetized with isoflurane (maintenance 2%) in oxygen, intubated, and artificially ventilated (SAR-830; CWE Inc.) 5, 6 . The femoral artery was cannulated for recording mean arterial pressure (MAP) and for collection of blood samples. The femoral vein was used for AngII administration. Rectal temperature was maintained at 37°C. After surgery, anesthesia was maintained with urethane (750 mg/kg; i.p.) and chloralose (50 mg/kg; i.p.), and monitored by testing corneal reflexes and motor responses to tail pinch 5, 6 .
Monitoring of CBF
A portion of the parietal bone and underlying dura were removed, and a 2x2 mm region of the cerebral cortex, including the whisker-barrel area, was superfused with a modified Ringer's solution (37°C; pH: 7.3 to 7.4) 6 . CBF was monitored in the window with a laserDoppler probe (Periflux System 5010, Perimed A.B.). The outputs of the flowmeter and blood pressure transducer were connected to a computerized data acquisition system (MacLab). CBF was expressed as percentage increases relative to the resting level. Zero values were obtained after the heart was stopped by an overdose of isoflurane. 
Pharmacological agents
Experimental protocol
Procedures for CBF recording in mice and for AngII administration have been published previously [5] [6] [7] [8] [9] [10] and are summarized below. CBF recordings were started after MAP and blood gases were stable, (please see Table S1 at http://hyper.ahajournals.org). The cranial window was first superfused with Ringer's solution (vehicle), and CBF responses were recorded. The whisker-barrel cortex was activated for 60 seconds by stroking the contralateral vibrissae 5 , and the evoked changes in CBF were recorded. The endothelium-dependent vasodilator acetylcholine (ACh; 10µM; Sigma, St. Louis, MO) or the smooth muscle relaxant adenosine (400µM; Sigma, St. Louis, MO) was superfused on the exposed neocortex for 5 min. The concentration of ACh and adenosine were previously determined to elicit 50% of maximal responses 11 . After testing baseline CBF responses, saline or AngII were infused intravenously. The AngII infusion was adjusted to elevate MAP by 20 to 25 mm Hg gradually over 10 to 15 minutes until a stable increase was obtained 5, 6 . At this time, the infusion rate was 0.25±0.02µg/kg per minute, which produces elevations in plasma AngII within the upper range of those produced by endogenous activation of the renin-angiotensin system in rodents 12 . To avoid confounding effects of changes in resting tone, the concentration of AngII infused was selected not to alter resting CBF 5 . CBF responses elicited by whisker stimulation, ACh and adenosine were tested again after 30-40 minutes of AngII or saline infusion in wild type, EP1 or NOX2-null mice. In all experiments, AngII was infused once per animal. In experiments using pharmacological inhibitors, CBF responses were first tested with vehicle superfusion and then after 30 min of superfusion with SC51089 (10µM), SC560 (25µM), or NS398 (100µM). Then, the infusion of Ang II was started and CBF responses were tested again 30-40 minutes later. In some experiments, the effect of 30 min neocortical application of PGE 2 (1µM) or PGF2α (1µM) on the CBF responses was evaluated after AngII or saline infusion in mice treated with SC560 or in EP1 and NOX2-null mice. The specificity and selectivity of the inhibitors at the concentrations used was determined in previous studies 1, 3, 4 .
Immunohistochemistry
Mice (n=4/group) were perfused transcardially with PBS followed by 4% paraformaldehyde in PBS. Coronal brain sections (thickness: 20 µm) were cut through the somatosensory cortex using a cryostat. 
ROS detection
ROS production was assessed by hydroethidine (HE) microfluorography as previously described 2, 6, 8 . HE (2 µmol/L; Molecular Probes) was topically superfused on the somatosensory cortex for a total of 60 min (see below). The brain was removed, frozen, and coronal sections (thickness, 20 µm) were cut through cortex underlying the cranial window using a cryostat. Sections were analyzed using a Nikon Eclipse E800 fluorescence microscope equipped with a custom filter set for detection of HE oxidation products 2, 6, 8 . Images were acquired with a digital camera (Coolsnap, Roper Scientific) and analyzed in a blinded manner using the IPLab software (Scanalytics), as described 2 . Fluorescent intensities of all sections (20 per animal) were added, divided by the total number of pixels analyzed, and expressed as relative fluorescence units (RFU). The protocol for these experiments was identical to that of the CBF experiments. Ringer's solution containing HE or HE plus SC51089, SC560, NS398, was superfused and, 30 min later, the i.v. infusion of AngII or vehicle was started. Mice were killed 30-40 min later for ROS determination as described above. In some experiments the effect of neocortical application of PGE 2 or PGF2α on ROS production after COX-1 or EP1 receptor inhibition was also studied after AngII or saline infusion.
Mice were surgically prepared as described above and killed after 30-40 min of i.v. AngII infusion. Samples were immediately collected from the somatosensory cortex and the renal medulla, weighed and frozen. Samples were homogenized and prostanoids extracted as previously described 1 . Prostanoid concentration was determined using an enzyme immunoassay kit 1 .
Data Analysis
Data are expressed as mean±SEM. Two group comparisons were evaluated using the Student's t-test. Multiple comparisons were evaluated by the analysis of variance and Tukey's test. Differences were considered statistically significant for p<0.05. Figure S1 : The increase in CBF induced by topical application of the smooth muscle relaxant adenosine is not altered in wild type (WT) or EP1-/-mice treated with AngII, with or without SC51089, SC560, NS398, PGE2, or PGF2a. n=5-6/group. Figure S3: COX-1 (red) immunoreactivity does not co-localize with the astrocytic marker GFAP (green) or the neuronal marker NeuN (green). EP1 receptor (green) immunoreactivity co-localizes with NeuN (red), but not with GFAP (red). Bar 10µm.
